Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
US Health and Human Services Secretary Sylvia M. Burwell announces new progams and financial incentives to help accountable care organizations (ACOs) and professional medical associations make the transition from fee-for-service to value-based healthcare delivery.
Converting to for-profit status has a positive influence on a hospital’s finances, but no effect on quality or mortality rates, found researchers from the Harvard School of Public Health and Brigham and Women’s Hospital.